Terms: = Endocrine gland cancer AND NFATC2, ENSG00000101096, 4773, Q13469, NFATP, NFAT1, KIAA0611 AND Treatment
4 results:
1. A Data-Driven Approach to Refine Predictions of Differentiated Thyroid cancer Outcomes: A Prospective Multicenter Study.
Grani G; Gentili M; Siciliano F; Albano D; Zilioli V; Morelli S; Puxeddu E; Zatelli MC; Gagliardi I; Piovesan A; Nervo A; Crocetti U; Massa M; Samà MT; Mele C; Deandrea M; Fugazzola L; Puligheddu B; Antonelli A; Rossetto R; D'Amore A; Ceresini G; Castello R; Solaroli E; Centanni M; Monti S; Magri F; Bruno R; Sparano C; Pezzullo L; Crescenzi A; Mian C; Tumino D; Repaci A; Castagna MG; Triggiani V; Porcelli T; Meringolo D; Locati L; Spiazzi G; Di Dalmazi G; Anagnostopoulos A; Leonardi S; Filetti S; Durante C
J Clin Endocrinol Metab; 2023 Jul; 108(8):1921-1928. PubMed ID: 36795619
[TBL] [Abstract] [Full Text] [Related]
2. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract] [Full Text] [Related]
3. The Effects of Analgesics and Local Anesthetics on Gene Transcription Mediated by nfatc2 and Sp1 in Pancreatic Carcinoma.
Malsy M; Graf B; Bundscherer A
Anticancer Res; 2019 Sep; 39(9):4721-4728. PubMed ID: 31519571
[TBL] [Abstract] [Full Text] [Related]
4. Restricted heterochromatin formation links nfatc2 repressor activity with growth promotion in pancreatic cancer.
Baumgart S; Glesel E; Singh G; Chen NM; Reutlinger K; Zhang J; Billadeau DD; Fernandez-Zapico ME; Gress TM; Singh SK; Ellenrieder V
Gastroenterology; 2012 Feb; 142(2):388-98.e1-7. PubMed ID: 22079596
[TBL] [Abstract] [Full Text] [Related]
